Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)

Autor:	Jan H. Tillisch, Anna Gawlinski, Samira Moughrabi, Gregg C. Fonarow
Rok vydání:	2001
Předmět:	Male medicine.medical_specialty Adrenergic beta-Antagonists Myocardial Infarction Physical exercise Angiotensin-Converting Enzyme Inhibitors Coronary Artery Disease Coronary artery disease Cohort Studies Hospitals University chemistry.chemical_compound Patient Education as Topic Internal medicine Preventive Health Services medicine Humans Myocardial infarction Exercise Aged Hypolipidemic Agents Aspirin biology Vascular disease Cholesterol business.industry Disease Management Cholesterol LDL medicine.disease Los Angeles Diet Hospitalization Treatment Outcome chemistry ACE inhibitor HMG-CoA reductase biology.protein Cardiology Patient Compliance Female Cardiology and Cardiovascular Medicine business medicine.drug Program Evaluation
Zdroj:	The American journal of cardiology. 87(7)
ISSN:	0002-9149
Popis:	Despite scientific evidence that secondary prevention medical therapies reduce mortality in patients with established coronary artery disease, these therapies continue to be underutilized in patients receiving conventional care. To address this issue, a Cardiac Hospital Atherosclerosis Management Program (CHAMP) focused on initiation of aspirin, cholesterol-lowering medication (hydroxymethylglutaryl coenzyme A [HMG CoA] reductase inhibitor titrated to achieve low-density lipoprotein [LDL] cholesterol
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22e08cdc7e90bbefda03a122ad4fa13a https://pubmed.ncbi.nlm.nih.gov/11274933 Zobrazit plný text záznamu Full Text from ScienceDirect